Close Menu

NEW YORK – Becton Dickinson announced on Friday that it has received the CE mark for an expanded clinical application of a test assess immune function in patients with COVID-19.

The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes can now be marketed in Europe to identify and enumerate T-cell subtypes in COVID-19 patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.